Clinical Trial Update: Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy, tolerability and safety of NVA237 in chronic obstructive pulmonary disease; results have been posted after complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-01-05